Dianon preclinical data

DIAN announced a second-generation prostate cancer test, PSA II, that recognizes free antigen, as opposed to the existing assays for the antigen that do not distinguish bound PSA from free PSA.

A study, to be presented this week at the meeting of the American Urological Association in Las Vegas, showed that the new test distinguished 30 percent of men with confirmed benign prostate hyperplasia, who had an abnormal result on the existing PSA test. The proportion of free to total PSA significantly differentiated between patients with benign and malignant disease (p=0.0004) while total PSA did not (p=0.13). The study is to be published in Urology. ...